Figure 5 Two approaches to therapeutic genome editing

Slides:



Advertisements
Similar presentations
Human primary cells These cells taken from living tissue are extremely accurate as they are literally coming from the source and are available from many.
Advertisements

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 BMI and cardiorespiratory fitness levels
Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 BMI and mortality in patients with heart failure
Genome-editing Technologies for Gene and Cell Therapy
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Evolution of genetic concepts underlying risk of cardiovascular disease Figure 1 | Evolution of genetic concepts underlying risk of cardiovascular.
Figure 1 Experimental design
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Global rates of sodium, fruit, and vegetable intake
Figure 1 Antiplatelet and anticoagulant pathways
Figure 1 Inducers of the NLRP3 inflammasome related
Figure 2 Size categorization of airborne pollutants
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 2 Three-year survival rates on the basis of body composition
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Figure 3 Proportion of patients for whom NEDA
Figure 2 Use of CRISPR/Cas9 for genome editing
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Proactive and reactive prevention of cardiovascular disease
Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 Proposed clinical approach in athletes
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Health-care system today
Figure 1 Cardiovascular risk and disease across the life-course
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Urol. doi: /nrurol
Figure 1 Decision tree integrating the assessment,
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 Examples of biomarker-guided trials
Nat. Rev. Cardiol. doi: /nrcardio
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Challenges for big data applications in cardiovascular care
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Effects of cardiovascular medication on the fetus
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Nephrol. doi: /nrneph
Figure 4 Observational studies on multiple treatment strategies
Nat. Rev. Cardiol. doi: /nrcardio
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Nat. Rev. Cardiol. doi: /nrcardio
Figure 1 Essential features and goals of a precision medicine system
Figure 1 Body sites of microbiota that influences atherosclerosis
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Figure 4 Electrocardiogram patterns associated with Brugada syndrome
Genome-editing Technologies for Gene and Cell Therapy
S. Tamir Rashid, Graeme J.M. Alexander  Journal of Hepatology 
Figure 2 Impaired mitochondrial capacity and function in heart failure
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Figure:
Nat. Rev. Cardiol. doi: /nrcardio
Cellular Alchemy and the Golden Age of Reprogramming
Presentation transcript:

Figure 5 Two approaches to therapeutic genome editing Figure 5 | Two approaches to therapeutic genome editing. a | In one approach, the genome-editing tools would be delivered directly into the body so that the genome editing can take place at the desired site in the genomes within the desired tissues in vivo. b | In another approach, the genome editing would take place ex vivo in patient-derived stem cells, which after editing could then be transplanted back into the patient or, more likely, differentiated into the desired tissue type and then transplanted. Strong, A. & Musunuru, K. (2016) Genome editing in cardiovascular diseases Nat. Rev. Cardiol. doi:10.1038/nrcardio.2016.139